794461-84-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Trifluoromethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine is used as a pharmaceutical intermediate for the development of new drugs and biologically active compounds due to its unique structure and properties.
Used in Organic Synthesis:
2-Trifluoromethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine is used as a valuable intermediate in organic synthesis, enabling the creation of various chemical compounds with potential applications in different industries.
Used in Anti-inflammatory Applications:
2-Trifluoromethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine is used as an anti-inflammatory agent, potentially providing relief from inflammation and related conditions.
Used in Antiviral Applications:
2-Trifluoromethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine is used as an antiviral agent, potentially offering protection against viral infections and contributing to the development of antiviral medications.

Upstream product

• 1108192-98-8 6-benzyl-2-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 16675-58-4 1-Benzyl-4-(1-pyrrolidinyl)-1,2,3,6-tetrahydro-pyridine 

Relevant academic research and scientific papers

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

A concise one-pot synthesis of trifluoromethyl-containing 2,6-disubstituted 5,6,7,8-tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines

5,6,7,8-Tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines with appended trifluoromethyl groups are valuable chemotypes in medicinal chemistry due to the presence of a partially-saturated bicyclic ring and metabolically-stable CF3 group. 1H NMR studies were used to optimize the preparation of such compounds, using a three-step/one-pot procedure, to provide novel 2,6-disubstitued derivatives with a tertiary-substituent. Racemic 2,6-disubstituted tetrahydroquinolines were separated by chiral HPLC to provide single enantiomers.